×

Biotech for driving change

Now YOU can invest and become a shareholder in the company aiming to drive change on the biotechnology market

0
Investors
$ 0
Raised

Our Vision

We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing

Market

The market is driven by favorable government initiatives owing to the growth of the biotechnology sector in developing countries, such as India and China. Government initiatives are oriented towards modernizing the drug regulatory pathway, standardizing clinical studies, improving reimbursement policies, and speeding up the product approval process, thereby offering lucrative growth opportunities to the market. In addition, in 2019, small molecules dominated the pharmaceutical compounds pipeline with around 22 U.S. FDA approvals as compared to eight large molecules (biotech). Around 4 out of every 10 drugs are biotech derived,  This is driving the influx of emerging and innovative biotechnologies companies, further boosting the market revenue.

Why Invest with us?

ROI

Investors are treated like a bank with a better-than-average fixed rate of return of 12%

Growth

Investors are treated like a bank with a better-than-average fixed rate of return of 12%

Market

Investors are treated like a bank with a better-than-average fixed rate of return of 12%

Raised

Investors are treated like a bank with a better-than-average fixed rate of return of 12%

Investment Summary

As Featured On

Incentives and Bonus

Investors who purchase over $25,000 worth of stock will receive 3 free months of ownership & service subscription*

Investors who purchase over $50,000 worth of stock will receive 6 free months of ownership & service subscription**

The investor who purchases the most stock in this campaign will receive a free all-expenses-paid trip for two to Atlis Headquarters in Mesa, AZ to test drive the XT, tour Atlis HQ, and meet the Atlis team.

Our Team

LEADERSHIP TEAM: HIGH-HORSEPOWER WITH AN INNOVATIVE TRACK RECORD

team_2

Caroline Merck

SVP Investor Relations